Merck Targets Sandoz, Intas Over Generic Emend Plans
Merck Sharp & Dohme Corp. is suing Novartis AG unit Sandoz Inc. and India-based Intas Pharmaceuticals Ltd., claiming their plans to make a generic version of Merck's anti-nausea drug Emend would...To view the full article, register now.
Already a subscriber? Click here to view full article